Drug Profile
Research programme: aurora kinase A inhibitors - Viracta Therapeutics
Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Sunesis Pharmaceuticals
- Class
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 03 Jun 2008 Discontinued for Cancer in USA (unspecified route)
- 26 Mar 2008 Early research in Cancer in USA (unspecified route)